Ardent Health's Earnings Call Contradictions: Professional Fee Growth Outlook, Seasonal Volume Guidance, and IMPACT Savings Nature Clash

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $1.62B

Guidance:

• Revenue for full-year 2026 now biased towards the lower end of the $6.4 to $6.7 billion range.
• Adjusted EBITDA guidance for full-year 2026 is reaffirmed at $485 to $535 million.
• Third quarter adjusted EBITDA expected to improve from Q2's $115 million and approach Q1's $124 million.
• Exchange headwind for 2026 reaffirmed at $35 million.

Business Commentary:

Operational Efficiency and Cost Management:

• Ardent Health's Salaries, Wages & Benefits (SW&B) grew by only 0.7% year-over-year, with a 42% reduction in contract labor spend.
• The company's focus on operational excellence and cost control, particularly through the "Impact" program, allowed them to manage costs effectively despite a challenging volume environment.

Payer Contracting and Revenue Yield:

• A key payer contract renewal in one market is expected to generate earnings above original 2026 plans, with a projected contribution of $5 to $10 million to adjusted EBITDA.
• This improvement is part of a broader strategy to enhance revenue yield through data-driven payer contracting, capitalizing on market rate opportunities.

Volume Trends and Strategic Response:

• Surgeries and admissions declined by 2.9% and 1%, respectively, in Q2, with a notable 5% drop in April and May.
• Ardent Health responded with decisive actions, including workforce reductions and structural changes, to offset volume-related earnings pressure, maintaining full-year adjusted EBITDA guidance.

Service Line Rationalization:

• The company is rationalizing its service lines, moving lower-margin procedures like ENT and ophthalmology out of hospitals to focus on higher-margin service lines such as cardiology.
• This strategic realignment is aimed at optimizing margins and aligning with market demand for specific services.

Virtual Care and AI Integration:

• The rollout of HelloCare AI in Texas and Idaho resulted in virtual nurses completing 58% of discharge duties, reducing patient monitoring hours by 18%.
• This initiative exemplifies Ardent Health's strategy to leverage technology for cost savings and improved operational efficiency.

Sentiment Analysis:

Overall Tone: Positive

• "I'm very pleased with how our team responded to a challenging volume environment..." "We have the right leadership team, strategy, and financial strength to execute on our plan and create long-term value for shareholders." "We're maintaining our outlook for full-year 2026 revenue and adjusted EBITDA... We remain confident..."

Q&A:

• Question from Anne Hines (Mizuho Securities): Just on the payer contract changes on the outpatient side, how many more markets do you think you have opportunities to get to market rates?
  Response: Management sees opportunity for improvement across most markets due to a more integrated, data-driven revenue cycle management approach.

• Question from Anne Hines (Mizuho Securities): And just as a follow-up on the surgery, your inpatient surgeries declined much more than outpatient... What was driving that decline?
  Response: The steeper inpatient decline was primarily due to a shift from inpatient to outpatient procedures, largely driven by procedures moving off the inpatient-only list, with a modest net financial impact of $1-2 million.

• Question from Jason Casorla (Guggenheim): Maybe just to follow up on the volume side... Was that recovery in June and July broad-based? And then the second half expectation... based on how you're seeing pressures... would you consider 2026 as effectively an easy comp?
  Response: Volume recovery in June/July was broad-based. The second half outlook assumes Q2 volume levels, not the stronger June/July trends, with management planning for various scenarios. Future growth will be based on meeting consumer needs and managing pent-up demand.

• Question from Jason Casorla (Guggenheim): Are there any benchmarking or contracting... that gives you visibility or confidence that you won't see like a further stepped up pressure for professional fees or denials?
  Response: Professional fee growth is expected to slow in the back half. Denial trends have been stable; management is working closely with revenue cycle partners and using AI to improve, with no evidence of escalation so far.

• Question from Matthew Gilmore (KeyBank): Maybe starting off on the service line rationalization... and what the opportunity is... And then... how we should expect that to impact the surgical metrics...
  Response: Service line rationalization is early; work is ongoing to optimize margins and focus on high-value service lines like cardiology. Surgical volumes for the back half are expected to remain at Q2 low single-digit decline levels, with optimization taking time to implement.

• Question from Matthew Gilmore (KeyBank): And then on the exchange topic... what you thought would cause the exchange headwind to grow in the back half.
  Response: Headwind growth was expected throughout the year; some macroeconomic pressures may have caused individuals to lose coverage, but trends have been better than initial assumptions, with movement to other coverage types providing some optimism.

• Question from Ben Hendricks (RBC Capital Markets): I was hoping you could provide a little more detail on some of the paramix dynamics that you saw in the quarter.
  Response: Exchange pressure and growth in self-pay were seen, but a material portion of individuals losing exchange coverage moved to other forms of coverage, both commercial and governmental, indicating some optimism.

• Question from Ben Hendricks (RBC Capital Markets): And just a real quick follow-up on your outpatient contracting commentary. You noted opportunities for continued contracting benefits in other markets. Just wanted to get a sense of how much of a gating item that is for continued ASC development...
  Response: Outpatient contracting and ASC development go hand in hand and must be tightly coordinated; one influences the other.

• Question from Kevin Fishbeck (Bank of America): I just want to follow up on the volume commentary first. Is there a good theory for why April and May would have been so weak and then June and July having come back?
  Response: The pronounced weakness in April/May is attributed to macroeconomic pressure, particularly in coverage areas with high deductibles, while more stable demand was seen in Medicare/Medicaid. The rebound in June/July is encouraging but volatile.

• Question from Kevin Fishbeck (Bank of America): And then I guess on the repricing dynamic... Should we be thinking about that type of size across multiple markets?
  Response: The $5-10 million benefit was from one large contract in one market. Opportunities exist across markets, but negotiations are hard and take 2-3 years, with a focus on data-driven, partnership-based discussions.

• Question from Scott Fidel (Goldman Sachs): For the first question, Dave, I wanted to ask you a strategy question... how those line up. And especially just... because clearly this is going to drive some of your capital considerations.
  Response: The existing growth strategy remains focused on right markets, disciplined M&A, and JV partnerships. JV relationships are improving results, and the company is taking a deeper look at all assets for optimization, but no major strategy pivots are planned.

• Question from Scott Fidel (Goldman Sachs): And then just on the follow-up... I'm curious if... you could share with us in terms of, you know, what percentage are going uninsured versus finding additional coverage?
  Response: For the cohort of individuals seen last year and this year, a very material amount are finding incremental coverage, though tracking methods vary.

• Question from AJ Rice (UBS): I just wanted to ask you about first some of the other expense areas where you seem to have done pretty well, salaries and benefits and supplies.
  Response: Expense management was strong, particularly in SW&B where cost control was quick. More opportunity exists in the supply chain, but impact takes longer to realize.

• Question from AJ Rice (UBS): And then maybe for the follow-up... are you allowing at all for a seasonal pickup later in the year... How does the comparison look versus last year?
  Response: A normal seasonal pickup is expected off a lower base, with H2 typically stronger than H1, but not factored into the outlook. Pent-up demand and economic uncertainty could lead to a stronger-than-normal season, but that's not assumed.

• Question from Craig Kettenbach (Morgan Stanley): Dave, going back to your comments about the top of funnel and 25 urgent care and ASCs, can you just talk about kind of the pipeline and any updated stats you can share.
  Response: Top-of-funnel metrics like referrals and patient transfers are showing low double-digit growth, which is critical for inbound patient flow and financials, providing positive signals.

• Question from Craig Kettenbach (Morgan Stanley): And then maybe building on the hello.ai, you know, AI commentary... anything else you would share on just kind of the rollout of that...
  Response: HelloCare AI is ROI positive for virtual sitting, reducing patient falls and improving oversight. Ambient listening (scribes) has achieved >mid-single-digit productivity gains for providers, with ongoing work to best utilize that time savings.

• Question from Benjamin Rossi (JP Morgan): Regarding the impact program... do you think the incremental benefit realization is largely coming from pull forward on other initiatives... Or did you see opportunity open up as surgical volumes were coming in softer?
  Response: The incremental savings in June were largely a pull forward, as the Impact program is accelerated faster than in the past. The inventory of opportunities is expanding, but the current actions are focused on executing the existing plan with speed and design.

Contradiction Point 1

Outlook on Professional Fee Growth

Contradictory statements on whether the year-over-year growth trend for professional fees is slowing or expected to moderate.

Jason Casorla (Guggenheim) - Jason Casorla (Guggenheim)

2026Q2: The year-over-year trend is expected to slow in the back half of 2026. - Alfred Lumsdain(CFO)

Given past step-ups in professional fees and denial trends around Q2/3, what gives you visibility and confidence that further stepped-up pressure won't occur? - Kevin Fischbeck (BofA Securities)

2026Q1: Professional fee growth is expected to moderate to high-single digits in the back half of 2026, down from the double-digit trajectory seen recently. - Alfred Lumsdaine(CFO)

Contradiction Point 2

Seasonal Volume Expectations

Contradiction on whether a normal seasonal pickup in the second half is expected or factored into guidance.

AJ Rice (UBS) - AJ Rice (UBS)

2026Q2: A normal seasonal pickup is expected, but it will be off a lower base... The Impact program and new initiatives... will improve the ability to handle patient flow efficiently. - Alfred Lumsdain(CFO)

Are you factoring in a seasonal pickup in utilization later this year, and how does this compare to last year? - Jason Cassorla (Guggenheim Securities, LLC)

2026Q1: Typically, Q4 is the strongest seasonally, and Q1 is the weakest. Q2 and Q3 are usually comparable, but Q2 might see a modest step-up... - Alfred Lumsdaine(CFO)

Contradiction Point 3

Nature of Exceeding Care Savings

Contradiction on whether savings from the IMPACT program are primarily new initiatives or a pull-forward of existing plans.

Benjamin Rossi (JP Morgan) - Benjamin Rossi (JP Morgan)

2026Q2: The savings realized so far in 2026 are largely a pull forward and acceleration of the multi-year Impact program. - Alfred Lumsdain(CFO)

Are the incremental savings in the Impact program primarily due to pulling forward initiatives or new opportunities from softer volumes? - Jason Cassorla (Guggenheim Securities, LLC)

2026Q1: The $35M EBITDA headwind from exchanges... The IMPACT program throughput is expected to drive a modest step-up... - Alfred Lumsdaine(CFO)

Contradiction Point 4

Exchange (HIX) Enrollment Impact and Outlook

Contradiction in the characterization of enrollment pressure and its financial impact for the upcoming year.

Can you discuss your guidance for the next fiscal quarter? - Matthew Gilmore (KeyBank)

2026Q2: Trends are expected to grow throughout the year, as seen from Q1 to Q2. While some of the pressure may be due to economic factors causing people to lose coverage, the company remains comfortable with the $35 million net impact for the year. There may be some conservatism, but the team is being thoughtful and planful. - Alfred Lumsdain(CFO)

What factors are expected to cause the exchange headwind to grow in the back half, and is there conservatism in the guidance? - Ann Hynes (Mizuho Securities):

20260305-2025 Q4: Enrollment is expected to decline by about 20% in 2026, with 10-15% shifting to employer-sponsored coverage and the rest to self-pay. Utilization for this cohort is expected to be 30% lower. The Q1 revenue impact will depend on the grace period and timing of disenrollment. - Martin Bonick(CFO)

Contradiction Point 5

Outlook on 2026 EBITDA Growth and Margin Expansion

Contradiction on the achievability of mid-teens EBITDA margins in the near term.

Jason Casorla (Guggenheim) - Jason Casorla (Guggenheim)

2026Q2: The outlook is in a fluid environment... While there is pent-up demand... the leadership team is focused on having the right cost structure and projects lined up for success regardless of volume. - Dave Kaspers(CEO), Alfred Lumsdain(CFO)

Was the June/July recovery broad-based or within select service lines, and for the second half, are you assuming the Q2 run rate or the improved June/July rate? Given this year's pressures, is 2026 an easy comp or the new baseline for growth? - Raj Kumar (Stephens)

2025Q3: Near-term headwinds would extend the timeline to reach mid-teens margins. The company is accelerating the IMPACT program to create offsets and will provide a better framing of timelines in the 2026 guidance. - Alfred Lumsdaine(CFO)